Constantiam Biosciences Inc.

Constantiam Biosciences Inc. is a for-profit corporate entity registered in SAM.gov, specializing in advanced computational genomics and bioinformatics technologies. The company develops innovative software platforms and computational approaches to support clinical genetic variant interpretation, with a focus on leveraging multiplexed assays of variant effect (MAVEs) to improve genetic testing and disease risk assessment. Their technological solutions aim to address critical challenges in genomic research, particularly around classifying variants of uncertain significance (VUS) in genetic testing for complex diseases like Alzheimer's, cancer, and cardiovascular conditions.

Through federal grant awards, primarily from civilian agencies like the National Human Genome Research Institute and the National Institute on Aging, Constantiam Biosciences has developed two key technological platforms: Varify and MAVEvidence. These platforms utilize advanced computational methods, including Bayesian inference and probabilistic programming, to analyze complex genetic variant data. Their recent federal grant awards, totaling over $900,000, have supported the development of technologies that can rapidly process and interpret large genetic datasets, specifically focusing on improving variant classification for Alzheimer's disease risk genes (such as APP and SNCA) and cancer-related genes (like BRCA1 and PTEN). The company's SBIR (Small Business Innovation Research) grants demonstrate a strategic approach to developing commercial-ready products that can significantly reduce the time and complexity of genetic variant interpretation for diagnostic laboratories and genetic testing companies.